ReviewJournal of biomolecular screening2014
Inhibition of microglia activation as a phenotypic assay in early drug discovery.
Review in Journal of biomolecular screening, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Demethyleneberberine, a potential therapeutic agent in neurodegenerative disorders: a proposed mechanistic insight.Molecular biology reports · 2022Pooled it
- First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers.Clinical pharmacology in drug development · 2021Trial
- Comparative Analysis of Red Onion-Derived Exosome-Like Nanovesicles and Extract Reveals Sustained Immunomodulatory Effects in LPS/IFN-γ-Stimulated Microglia.Molecular neurobiology · 2026Article
- Relationship of S100 Proteins with Neuroinflammation.Biomolecules · 2025Review
- Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders.Current issues in molecular biology · 2025Review
- Bioactive Potential of Sweet Cherry (Foods (Basel, Switzerland) · 2025Article
- Advanced theragnostics for the central nervous system (CNS) and neurological disorders using functional inorganic nanomaterials.Advanced drug delivery reviews · 2023Review
- Morphological screens using aged primary adult neuronal, microglial, and astrocytic cultures to find novel neurotherapeutics.Frontiers in cellular neuroscience · 2023Article
- LPS-induced lipid alterations in microglia revealed by MALDI mass spectrometry-based cell fingerprinting in neuroinflammation studies.Scientific reports · 2022Article
- An insight into the neuroprotective and anti-neuroinflammatory effects and mechanisms ofFrontiers in pharmacology · 2022Review
- Mechanisms of Mitochondrial Dysfunction in Lysosomal Storage Disorders: A Review.Journal of clinical medicine · 2020Review
- Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APPswe/PS1dE9 Alzheimer's Disease Mouse Model.Journal of Alzheimer's disease : JAD · 2019Article
- The human microglial HMC3 cell line: where do we stand? A systematic literature review.Journal of neuroinflammation · 2018Review
- Role of microglia under cardiac and cerebral ischemia/reperfusion (I/R) injury.Metabolic brain disease · 2018Review
- Article
- Advances in Drug Discovery and Development in Geriatric Psychiatry.Current psychiatry reports · 2018Review
- Effect of Chlorogenic Acid Supplementation in MPTP-Intoxicated Mouse.Frontiers in pharmacology · 2018Article
- Article
- Development of a primary microglia screening assay and its use to characterize inhibition of system xBiochemistry and biophysics reports · 2017Article
- Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Complex biological processes such as inflammation, cell death, migration, proliferation, and the release of biologically active molecules can be used as outcomes in phenotypic assays during early stages of drug discovery. Although target-based approaches have been widely used over the past decades, a disproportionate number of first-in-class drugs have been identified using phenotypic screening. This review details phenotypic assays based on inhibition of microglial activation and their utility in primary and secondary screening, target validation, and pathway elucidation. The role of microglia, both in normal as well as in pathological conditions such as chronic neurodegenerative diseases, is reviewed. Methodologies to assess microglia activation in vitro are discussed in detail, and classes of therapeutic drugs known to decrease the proinflammatory and cytotoxic responses of activated microglia are appraised, including inhibitors of glutaminase, cystine/glutamate antiporter, nuclear factor κB, and mitogen-activated protein kinases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.